Blog
RSS FeedPosted by Michael Wonder on 07 Jun 2017
Converging on the value of value frameworks
6 June 2017 - The relentless increase in health care costs has been difficult to control and is widely believed to ...
Posted by Michael Wonder on 27 May 2017
Dr Steve Pearson outlines the importance of thresholds on determining value
23 May 2017 - Thresholds can be useful to focus the conversation around the value of treatments in healthcare even if ...
Posted by Michael Wonder on 22 May 2017
Another voice: Patients have a right to the treatments ordered by doctors
22 May 2017 - For too long, insurance-backed groups have been given enormous power to overrule doctors’ orders and make ...
Posted by Michael Wonder on 13 May 2017
Institute for Clinical and Economic Review releases revised evidence report on dupilumab and crisaborole for treatment of atopic dermatitis
12 May 2017 - Limitations noted on the evidence for crisaborole; analyses find stronger evidence for dupilumab and suggest its price ...
Posted by Michael Wonder on 11 May 2017
Institute for Clinical and Economic Review posts briefing paper on assessing the value of drugs for rare conditions
10 May 2017 - Report contains a technical brief on Spinraza and will inform discussions at ICER pricing summit on 31 ...
Posted by Michael Wonder on 08 May 2017
Institute for Clinical and Economic Review posts draft scoping document on treatments for tardive dyskinesia, including recently approved Ingrezza
8 May 2017 - Report expected to review evidence on deutetrabenazine (Austedo), tetrabenazine (Xenazine), and valbenazine (Ingrezza); scoping document will be ...
Posted by Michael Wonder on 07 May 2017
Institute for Clinical and Economic Review's draft evidence report on abuse-deterrent opioids evaluates clinical and economic evidence on nine formulations
5 May 2017 - Public comment period now open until 2 June; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 04 May 2017
ICER releases draft evidence report on treatments for osteoporosis, including abaloparatide and romosozumab
3 May 2017 - Abaloparatide recently approved by FDA, romosozumab under FDA review; public comment and requests to give oral comment ...
Posted by Michael Wonder on 22 Apr 2017
Institute for Clinical and Economic Review to review drugs for tardive dyskinesia in upcoming report
21 April 2017 - Report expected to include review of Ingrezza, recently approved, and Austedo, currently under FDA review; ICER's open ...
Posted by Michael Wonder on 12 Apr 2017
Pharmacy benefit management companies: do they create value in the US health care system?
12 April 2017 - Pharmacy benefit management companies perform functions in the US market-based healthcare system that may be performed by ...
Posted by Michael Wonder on 11 Apr 2017
ICER posts draft scoping document on cognitive and mind-body interventions to treat chronic low back and neck pain
10 April 2017 - Report expected to review evidence on acupuncture, cognitive behavioural therapy, mindfulness, yoga, and tai chi; scoping document ...
Posted by Michael Wonder on 07 Apr 2017
Institute for Clinical and Economic Review's final report on treatments for rheumatoid arthritis finds evidence inadequate to distinguish overall benefits between newer agents and prices too high in relationship to the clinical value provided to patients
7 April 2017 - Final report and meeting summary reviews evidence on 11 targeted immune modulator drugs, including two currently under ...
Posted by Michael Wonder on 24 Mar 2017
ICER releases draft evidence report on crisaborole and dupilumab for atopic dermatitis
24 March 2017 - Public comment period open until 21 April. ...
Posted by Michael Wonder on 20 Mar 2017
Institute for Clinical and Economic Review to review certain non-pharmacologic interventions for chronic low back and neck pain in upcoming review
20 March 2017 - The Institute for Clinical and Economic Review will develop a report assessing the comparative clinical effectiveness ...
Posted by Michael Wonder on 18 Mar 2017
Institute for Clinical and Economic Review to produce "New Evidence Update" Including updated value-based price benchmarks for PCSK9 inhibitors to treat high cholesterol
17 March 2017 - Update will incorporate new data on outcomes for patients with atherosclerotic cardiovascular disease released during the ...